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ABSTRACT
Background. The importance of functional outcome (FO)
in the treatment of patients with extremity soft tissue sar-
coma (STS) has been increasingly recognized in the last
three decades. This systematic review aimed to investigate
how FO is measured in surgically treated lower-extremity
STS patients.
Methods. A systematic search of PubMed, Web of Sci-
ence, and Scopus was performed based on the PRISMA
guidelines. The methodologic quality of the publications
was measured using the MINORS tool. The results from
the included studies examining measurement types, mea-
sures, and time of FO measurement were compiled. The
FO pooled mean and standard deviation were calculated as
a weighted average for the groups. The validity of the
applied measures is reported.
Results. The literature search found 3461 publications, 37
of which met the inclusion criteria. The measurement types
used were clinician-reported outcomes (n = 27), patient-
reported outcomes (n = 20), and observer-reported out-
comes (n = 2). The most frequently used measures were
the Toronto Extremity Salvage Score (TESS) (n = 16) and
the Musculoskeletal Tumor Society (MSTS) score 1993
(n = 12). The postoperative FO was relatively good. The
pooled mean TESS and MSTS 1993 scores were respec-
tively 83.3 and 86.2 (out of 100). Of the 10 previously
reported measures, 3 provide validated FO scores. The
methodologic quality of publications was generally low.
Conclusions. Based on this systematic review, several
different methods exist for assessing FO in patients with
lower-extremity sarcoma. The most frequently used mea-
sure is a validated TESS. The postoperative FO of patients
with lower-extremity STS seems to increase to the preop-
erative baseline level during long-term follow-up
evaluation.
In the last 30 years, limb salvage has become the stan-
dard of care in the treatment of extremity sarcoma, and
amputations are rare. This has been achieved by improved
diagnostics, pre- and postoperative radiotherapy, and more
refined reconstructive surgical methods. Reports on func-
tional outcome (FO) have been increasing.1–3
Several methods for assessing FO have been described,
including subjective and objective measures.2–4 Functional
outcome measures should be valid, reliable, accurate, and
clinically meaningful for the population in which the
measurement is made.5,6 Consistent usage of the same
measures allows benchmarking and comparison of study
results over time and between research centers.
A few previous review studies have considered the topic
from different perspectives. The review by Davis4 focused
on FO of all extremity tissue sarcoma patients, including
upper extremities and bone sarcomas. Tang et al.3 inves-
tigated quality-of-life studies in adult extremity sarcomas
(also including upper extremities and bone sarcomas) and
all quality-of-life studies. Furtado et al.2 reviewed physical
functioning after treatment for lower- and upper-extremity
sarcoma patients, including both bone and soft tissue
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sarcoma (STS). Only objective measures investigating
postural balance, gait, and physical activity were included.
All patient-reported outcome (PRO) measurement studies
were excluded. Groundland et al.7 investigated pediatric
patients. Wilson et al.8 studied pelvic sarcoma patients, and
Winnette et al.9 investigated all patients with STS,
including abdominal sarcomas. Thus, no systematic liter-
ature review has previously focused specifically on
measurement of FO after surgical treatment of adult lower-
extremity STS patients.
This study aimed to identify how FO has been measured
in patients with surgically treated lower-extremity STS.
More specifically, we sought to determine the type of
methods and measures used to measure FO, whether the
measures used had been tested for validity, FO for lower-
extremity STS patients, and quality of the publications that
report FO.
MATERIALS AND METHODS
Overview and Eligibility Criteria for Review
A systematic literature review was performed based on
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines.10 A review protocol
was created by the authors and is available on request.
The study included all publications concerning patients
with surgically treated lower-extremity STS whose FO was
measured. The exclusion criteria ruled out duplication,
studies that included fewer than 20 lower-extremity STS
patients (considered pilot studies),11 non-adult study pop-
ulations, and publications in languages other than English.
In the current review, the measures for assessing FO
were classified as ‘‘previously developed and reported
measures’’ or ‘‘new measures developed by the authors.’’
The ‘‘previously developed and reported measures’’ were
defined as measures developed to assess FO and published
previously. Measures, scales, or questionnaires developed
by the authors themselves with the purpose to assess FO
only in the reviewed article were considered ‘‘new mea-
sures developed by the authors.’’
To report the type of measurement applied for assess-
ment of FO, we used the terms ‘‘patient-reported
outcome,’’ ‘‘clinician-reported outcome,’’ ‘‘observer-re-
ported outcome,’’ and ‘‘performance outcome’’ measures.12
Patient-reported outcome (PRO) measures are based on a
patient’s subjective assessment. Clinician-reported out-
come measures are based on evaluation by a trained health
care professional. Observer-reported outcome measures are
based on observation by a person other than the patient or a
health professional. Performance outcome is based on
measurement of performance in specific tasks and are
considered objective measures.
Search Methods
PubMed, Scopus, and Web of Science search engines were
used for the search. All published articles were retrieved
without a search time constraint on 5 May 2018. The key-
words combined with Medical Subject Headings (MeSH)
terms were ‘‘lower AND (limb OR limbs OR leg OR legs OR
extremity OR extremities OR foot) AND sarcoma AND
(functional OR functionality OR function OR outcome).’’
Two authors (G.K. and M.K.) independently reviewed
all titles and appropriate abstracts. All unsuitable articles
were excluded by the previously mentioned exclusion cri-
teria. A manual search was performed for all references of
suitable studies by review of titles and appropriate
abstracts. The included studies were reviewed and added to
the final list by the set inclusion criteria. Disagreements in
data extraction were resolved by discussion and consensus
of the authors (G.K., M.K., K.K., J.R., and I.B.R.).
Study Data
Two authors (G.K. and M.K.) independently collected
the following information from the included publications:
study period, origin of the study, article type, anatomic
location of the tumor, number of patients, age, diagnosis,
measures and measurement types used for assessing FO,
results of FO, and follow-up time. In case of missing data,
an e-mail requesting additional information was sent to the
corresponding authors.
Validity Assessment
In this review, a validated FO measure is defined as a
measure that has been scientifically validated to assess FO
in extremity tumor patients. A literature search was per-
formed to detect suitable literature concerning the validity
of the FO measures.
Functional Outcome
In this review, FO is reported from publications that
used validated FO measures, and FO results are presented
as means ± standard deviations (SDs). The pooled mean
and SD were calculated as a weighted average of SDs for
the groups. Publications reporting FO for bone sarcoma or
upper-extremity STS patients in addition to lower-ex-
tremity STS patients were included in the FO report.
Quality of Publications Assessment
Because the quality of a publication can be measured
according to many different criteria, and because the validity
of these criteria have not been determined, quality was not
4708 G. Kask et al.
used to exclude studies in this review.13 The Methodological
Index for Nonrandomized Studies (MINORS) quality
assessment tool was used to assess the quality of publica-
tions.14 The MINORS tool is a valid instrument designed to
assess the methodologic quality of nonrandomized surgical
studies, either comparative or noncomparative.14 We used the
MINORS tool to assess the quality of randomized controlled
trials (RCTs), as has been done in previous literature.15
The MINORS tool consists of the following 12
methodologic items for studies: a clearly stated aim,
inclusion of consecutive patients, prospective collection of
data, end points appropriate for the aim of the study,
unbiased assessment of the study end point, follow-up
period appropriate for the aim of the study, less than a 5%
loss to follow-up evaluation, and prospective calculation of
the study size. Additional criteria for comparative studies
include adequate statistical analyses, an adequate control
group, contemporary groups, and baseline equivalence of
groups. The items are scored as follows; 0 (not reported), 1
(reported but inadequate), or 2 (reported and adequate).
The maximum score is 16 for non-comparative studies and
24 for comparative studies.14 Results are reported as per-
centages from 0 to 100.
RESULTS
Study Selection
Details of the literature search are presented in Fig. 1.
For the final review, 37 publications were selected.16–52
Study Characteristics
The included studies were published between 1984 and
2018. Of the 31 retrospective and 6 prospective studies, 3
were RCTs. Of the 37 studies, 25 were cross-sectional, 7
Records identified through 
database searching
(n = 431)
Sc
re
en
in
g
In
cl
u
de
d
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n
Records after duplicates removed
(n = 312)
Records screened
(n = 312)
Records excluded
(n = 204)
Full-text articles assessed 
for eligibility
(n = 108) 
Full-text articles excluded
due to:
Not FO study (n=25)
<20 patients (n=20)
Bone sarcomas (n=17)
Not lower extremity 
study (n=5)
Validation study (n=3)
Pediatric study (n=2)
Studies included in 
qualitative synthesis
(n = 37) 
Studies included in 
quantitative synthesis 
(n = 37)
Literature review search found 3461
publications
FIG. 1 Flow diagram showing flow of studies retrieved for systematic review of functional outcome measurement in patients with lower-
extremity soft tissue sarcoma
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were cohort, and 2 were case–control studies. The sample
sizes of the studies ranged from 25 to 728 patients. The
characteristics of the articles and the FO measurements are
presented in Table 1.
Type of Measurement to Assess FO
A single PRO measurement was used in 8 of the 37
publications, and a clinician-reported outcome measure-
ment was used in 17 of the 37 publications. The PRO and
clinician-reported outcome measurement types were used
together in 10 studies. The PRO and observer-reported
outcome measures were used in two studies. No perfor-
mance outcome measurement was used. All six prospective
studies used clinician-reported outcome measures, and four
of these also used a PRO measure (Table 2).
FO Measures
The majority of the publications (27/37) used previously
reported measures. The most common measures were the
Toronto Extremity Salvage Score (TESS) (43%, n = 16)
and the Musculoskeletal Tumor Society (MSTS) score
1993 (32%, n = 12). A total of 10 different previously
reported measurement tools were used (Table 2). New
measures developed by the authors were used in 10 pub-
lications. Of the 27 publications, one previously reported
measure alone was used in 14 publications, two and three
measures in 6 publications each, and four measures in 1
publication.
The RAND-36 is multidimensional PRO questionnaire
identical to the Short Form 36 (SF-36) but uses a different
scoring method.35 In this review, RAND-36 and SF-36 are
reported together.
Timing of FO Measurement
In 4 (11%) of the 37 studies, FO was measured both pre-
and postoperatively.24,37,39,52 More than one postoperative
time point of measurement was used in 3 (8%) of the 37
studies.24,39,52 The time of FO measurement varied in the
31 retrospective studies. The inclusion criteria required a
minimum follow-up period of 1 year in most of the studies.
In 18 (58%) of the 31 retrospective studies and 12 (50%) of
the 24 retrospective cross-sectional studies, the FO was
measured at least 1 year after the surgery. The time point
of measurement was not reported in seven studies, and
additional information was not available. Additional details
are presented in Table 1.
Validity of the Measures
Validated FO measures were used in 23 (62%) of the 37
publications. the validated measures were the TESS1,53 and
MSTS 19854,71 and 19931,55 (Table 2). The SF-3656 vali-
dation also has been studied, but its validity as a extremity
FO measure in this population is questionable.1 In addition,
the validity of the Short Musculoskeletal Function
Assessment (SMFA) questionnaire,57,58 the Foot Function
Index (FFI),59,60 the Karnofsky score,61 and the Reinte-
gration to Normal Living Index (RNL)62,63 measures also
has been studied. However, these measures were studies in
a different population of patients or as a general FO mea-
sure, or both. No studies on the validity or reliability of the
modified International Society Of Limb Salvage (ISOLS)/
MSTS 199327 scoring system or the modified Convery
scale64 were found.
Functional Outcome
The TESS, MSTS 1993, or MSTS 1987 results were
presented in 23 of the 37 studies. In some studies, not all
the required results (mean or SD of FO results, number of
lower- vs upper-extremity patients, number of STS vs other
tumors) were presented. Additional information was
requested from 15 corresponding authors. Five replied,
with two supplying the requested additional information.
Of the 23 studies, 3 were excluded from our FO report.
The reasons were as follows: only the difference in means
was reported;18 several TESS scores from the same patients
were included (in lower-extremity patients, a mean of 2.6
TESS results for one patient was included);21 and two
studies used the same data set (a study by O’Sullivan was
excluded).39,52 Means and SDs for a study by Saebye
et al.19 were calculated using median and IQR results.65,66
The SDs for studies by Friedmann et al.28 and Pradhan
et al.33 were approximated based on range using the range
rule calculation formula (SD = [max - min]/4). The pre-
and postoperative function results are presented in Table 3.
After study selection and additional gathering of infor-
mation, some studies still included upper-extremity or bone
sarcoma patients.
The pooled mean and SD were calculated for TESS and
MSTS 1993 results. Of 19 studies, 2 were excluded due to
missing SD data. The pre- and postoperative TESS and
MSTS 1993 pooled mean and SD results are presented in
Fig. 2. Because not all the publications included only
lower-extremity patients, TESS results for both lower- and
upper-extremity STS patients were included in 2 of 3
preoperative and 5 of 12 postoperative studies. Similarly,
MSTS 1993 results included both lower- and upper-ex-
tremity STS patients in 1 of 2 preoperative and 5 of 9
postoperative studies. In 3 of 17 studies, the TESS (n = 2)
4710 G. Kask et al.
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FIG. 2 Pre- and postoperative TESS and MSTS 1993 pooled mean and SD results
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and MSTS 1993 (n = 1) results included other extremity
tumor patients in addition to STS patients. The number of
included patients is described in Table 3.
The preoperative pooled mean TESS and MSTS 1993
scores were respectively 83.3 and 86.6, and the postoper-
ative scores were respectively 83.3 and 86.2 (out of 100).
In the pooled mean and SD analysis, the proportion of
lower-extremity and STS patients were respectively 88%
and 94%.
As a sensitivity analysis, the mean overall postoperative
FO in publications including also upper-extremity or bone
sarcoma patients was investigated. In publications includ-
ing upper-extremity patients (7 of 17 publications), the
mean overall TESS score was 86.7 (5 publications), and the
MSTS score was 89.0 (5 publications). In publications that
included also bone sarcomas (3 of 17 publications), the
mean overall TESS score was 63.1 (2 publications), and the
MSTS score was 90.3 (1 publication).
Quality of Publications
The mean MINORS score was 62.2 (median, 62.4;
range, 31–92). For the three RCTs, the respective scores
were 96,39 96,52 and 88.36 For the observational studies, the
mean MINOR score was 60.2 (median, 62.5; range,
31–92). The MINORS scores for each study are presented
in Table 1.
DISCUSSION
Based on the current systematic literature review, the
most frequently used measurement types used to measure
FO for surgically treated adult lower-extremity STS
patients are clinician-reported outcome and PRO mea-
surements. The most frequently used measures are the
TESS and the MSTS 1993 questionnaires. Of the 10 pre-
viously reported measures, 3 were proven to provide valid
scores for lower-extremity sarcoma patients. Most of the
studies on lower-extremity STS FO have poor method-
ologic quality.
Methods and Measures of FO
The majority of the included studies used clinician-re-
ported outcome measurement. In the last 10 years, the use
of PRO measurements has increased. Furtado et al.2 con-
sidered performance outcome an important component of
FO in sarcoma patients. This clearly is a minority position
in their study because no performance outcome measure-
ment type was found. Performance outcome measurement
type has been used more frequently in publications with
smaller study samples.2 This may be due to the greater time
requirements and equipment and personnel costs required
for performance outcome measurements.2
In the literature review of Furtado et al.2 that investi-
gated performance outcome measurement techniques, the
study size ranged from 4 to 82 patients. In the current
review, one of the inclusion criteria was a minimum of 20
lower-extremity STS patients. In our study, the sample size
ranged from 25 to 728 patients.
When FO is assessed in a study, it is important to avoid
loss to follow-up evaluation. Loss to follow-up evaluation
less than 5% is indicated in the MINORS publications’
quality measurement tool as an indicator of a good-quality
study.14 More important than the measurement type is that
the outcome measure provide valid and reliable scores in
TABLE 2 Previously developed and reported patient-reported outcome (PRO) and clinician-reported outcome (ClinRO) tools
Measure Measurement
type
n Studies Valid
R (n = 31) P (n = 6) CS
(n = 25)
C (n = 7) CC (n = 2) RCT
(n = 3)
TESS PRO 16 12 4 7 5 1 3 ?
MSTS 1993 ClinRO 12 10 2 7 4 1 0 ?
MSTS 1987 ClinRO 7 4 3 1 3 0 3 ?
SF-36 PRO 7 5 2 3 1 1 2
SMFA PRO 1 1 0 1 0 0 0
FFI PRO 1 1 0 1 0 0 0
Karnofsky score ClinRO 1 1 0 1 0 0 0
Modified MSTS 1993 (ISOLS) ClinRO 1 1 0 1 0 0 0
RNL PRO 1 1 0 0 0 1 0
Convery scale ClinRO 1 1 0 1 0 0 0
R retrospective study, P prospective study, CS cross-sectional study, C Cohort study, CC Case–control study, RCT randomized clinical trial,
TESS Toronto extremity salvage score, MSTS Musculoskeletal Tumor Society, SMFA Short Musculoskeletal Function Assessment, FFI Foot
Function Index, ISOLS International Society Of Limb Salvage, RNL Reintegration to Normal Living, PRO patient-reported outcome, ClinRO
clinician-reported outcome
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TABLE 3 Pre- and postoperative function scores. Results of the TESS, MSTS 1993 and MSTS 1987 measures
Author Year LE
patients (n)
Mean TESS
(SD)a
Mean MSTS
1993 (SD)a
Mean MSTS
1987 (SD)b
Comments
Preoperative
Rivard 2015 35 79.8 (20.6) 78.8 (20.7) NA FO results including UE STS patients
(n = 15). Results available for MSTS from
45 and for TESS from 48 patients
Gerrand 2004 207 83.1 (20.1) 87.9 (19.6) NA Results available for MSTS from 203 and for
TESS from 172 patients
Davis 2002 147 84.4 (19.0) NA 26.8 (4.4) FO results including UE STS patients
(n = 38)
Postoperative
Saebye 2017 90 94 (11.3) 92.8 (13.6) NA FO results including UE STS patients
(n = 38)
Harati 2016 120 63.8 (17.0) NA NA FO results available for 30 patients
Chang 2016 129 NA 80.2 (NP) NA FO results including UE STS and other
tumors. Excluded from the pooled mean
and SD analysis due to missing SD data
Furtado 2015 37 56.4 (23.3) NA NA TESS results including bone sarcoma patients
(n = 63)
Rivard 2015 35 87.1 (16.6) 88.8 (11.9) NA FO results including UE STS patients
(n = 15). Results available for MSTS from
37 and for TESS from 41 patients
Kang 2014 104 NA 85.4 (13.9) NA FO result including UE STS patients (n = 44)
Townley 2013 21 84.76 (NP) NA 29.73 (NP) FO results including bone sarcoma patients.
Excluded from the pooled mean and SD
analysis due to missing SD data
Friedmann 2011 204 89.4 (32.4–100)c NA 32 (11–35)c FO results including UE STS patients
(n = 59)
Thacker 2008 52 NA 83.3 (11.5) NA FO results available for 30 sarcoma patients
Tsukushi 2008 25 NA 70 (NP) NA
Hoy 2006 70 NA 90.3 (NP) NA FO results including UE STS (n = 6) and
bone sarcoma (n = 39) patients
Pradhan 2006 184 77 (23–100)c NA NA FO results available for 70 patients
Nelson 2006 48 85.1 (19.3) NA NA FO results available for 34 patients
Davis 2005 100 83.2 (21.8) NA 28.9 (9.2) FO results including UE STS patients
(n = 29)
Gerrand 2004 207 82.7 (17.7) 85.8 (19.0) NA Results available for MSTS from 189 and for
TESS from 155 patients
Rachbauer 2003 29 NA 88.5 (NA) NA FO results including UE STS (n = 6) and
other anatomic location sarcomas (n = 4)
Davis 2002 147 80.3 (21.1) NA 28.6 (7.8) FO results including UE STS patients
(n = 38). Results available for MSTS from
163 and for TESS from 156 patients
Davis 2000 172 82.7 (18.7) 84.8 (20.4) 30.0 (6.2)
Davis 1999 29 81.6 (17.8) NA NA FO results including bone sarcoma patients
(n = 7)
Colterjohn 1997 29 NA NA 31.4 (4.6) FO results available for 26 patients
TESS Toronto extremity salvage score, MSTS Musculoskeletal Tumor Society, LE lower-extremity, SD standard deviation, NA not available, NP
not presented, UE upper extremity, STS soft tissue sarcoma, FO functional outcome
aScores are presented as range of 0 (minimum) to 100 (maximum)
bScores are presented as range of 0 (minimum) to 35 (maximum)
cRange (min–max)
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measuring FO. However, the type of measurement should
be chosen based on the objectives of the assessment, the
available resources, and the aspects of FO that are of
interest.
According to the current review, the TESS and MSTS
1993 questionnaires have been used most frequently. Tang
et al.3 observed that the most frequently used outcome
measures were the TESS, the MSTS 1987, and the SF-36.
However, they observed that the TESS was used only four
times, the MSTS 1987 three times, and the MSTS 1993 two
times. They also found that when the MSTS was used, the
1987 version was preferred. Likewise, Groundland et al.7
found that the MSTS is the most widely used FO measure
for pediatric patients after limb-preservation surgery.
Winnette et al.9 investigated patient experience with
STS in all anatomic locations, including abdominal sar-
comas. They found that in extremity patients, the RNL and
the TESS were used three times each. The MSTS ques-
tionnaire was not presented in their review because it
examined only PRO measures.
Wilson et al.8 found that the MSTS was the most fre-
quently used measure and that the TESS was presented
only once for pelvic sarcoma patients. Some studies have
used both the older and newer versions of the MSTS
questionnaires in the same study.18,41 Other measures such
as the SF-36, the FFI, the Karnofsky score, the RNL, the
SMFA, the modified MSTS 93/ISOLS, and the modified
Convery scale64 have been used but much less frequently.
The MSTS 198754 is a clinician-reported outcome
assessment that evaluates seven parameters of FO (mobil-
ity, pain, stability, deformity, strength, functional, and
emotional acceptance). The MSTS 1993,55 a revised ver-
sion of the MSTS 1987, also is assessed by physicians.
However, the MSTS 1993 is more limb-specific than the
older version and includes six parameters. Pain, function,
and emotional acceptance are measured for both extremi-
ties. For the lower-extremity, use of walking aids, gait, and
walking are evaluated. Hand positioning, dexterity, and
lifting ability are evaluated for the upper extremity.
The TESS was developed for limb sarcoma patients. As
a PRO questionnaire, it measures physical disability and
performance in activities of daily living.53 Janssen et al.67
found that the TESS has adequate coverage and is more
reliable than the MSTS questionnaire. In addition, they
found that the MSTS score is the least reliable, as indicated
by a high standard error of measurement for the complete
range of ability scores. Although both versions of MSTS
are the most frequently used tool for assessing FO, the
TESS tool is more frequently used than the two MSTS
versions separately. The TESS also was developed later
than the MSTS measures.53–55
The study by Tang et al.3 included only articles pub-
lished in last 10 years. The TESS was used in four
publications, the MSTS 87 in three publications, and the
MSTS 93 in two publications. Because of the relatively
wide use of MSTS scores, the MSTS questionnaires permit
comparison of results more easily and widely than in other
studies. On the other hand, the MSTS questionnaire must
be completed by a clinician, thus limiting its use in studies
with larger samples.
The TESS questionnaire was designed to be completed
by patients and can therefore be administered by mail or
electronically. This is important particularly in long-term
follow-up studies. Using the TESS may avoid the need for
a physician consultation, thus saving resources. Using PRO
measures may make it easier for patients to participate in
the study. Also, minimal clinically important differences
(MCIDs) are calculated for the TESS.68 Because the MSTS
measure was developed by orthopedics for surgically
treated bone and soft tissue musculoskeletal tumors, it may
not capture the effects of radiotherapy, chemotherapy, and
other factors that also affect FO.16,36,48,49,69 Although all
FO measurements have limitations, the use of standardized
instruments is important. Using the TESS and MSTS
measures allows for benchmarking and comparison of
results with other studies.
According to the results of our literature review, most
studies used only one FO measure. The use of more than
one FO measure provides more precise information on FO.
For example, the TESS measures activity limitations,
whereas the MSTS measures impairment in extremity
sarcoma patients.53,55 On the other hand, using too many
time-consuming questionnaires could lead to decreased
participation and loss to follow-up evaluation. In addition,
using more than one FO measuring tool might not be
clinically relevant.70 Study participants should be informed
about the patient burden, including how many items must
be completed, how long it takes to complete the ques-
tionnaires for participation in the assessment, and how
many assessments are made. Questionnaires implemented
in a clinical study should be carefully chosen to ensure that
they are fit for the purpose.71–74
Most retrospective studies required a minimum follow-
up period of 1 year after surgery. In addition, FO showed a
decrease up to 6 months after the surgery. Beyond 1 year,
FO plateaued before the scores returned to approximate
pre-treatment levels 1 year after surgery.39,43,75
Rivard et al.24 did not observe significant changes in the
TESS and MSTS scores from the preoperative period to
6 months after surgery. By 12 months, the scores showed
significant improvement. This is an important factor when
prospective data measurement in retrospective samples is
planned. In cross-sectional studies and other prospective
studies, it is important to consider measuring FO at least
1 year after the surgery, in addition to other measurement
time points.
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Validity of Measures
The validity of a measurement tool is a multi-dimen-
sional term. The most important measurement property is
content validity. The measure should be relevant, com-
prehensive, and comprehensible with respect to the
construct of interest and the study population.76 Structural
validity is the degree to which the scores adequately reflect
the dimensionality of the construct to be measured.39,77
This review considered the measure to be validated when it
was tested in lower-extremity patients and reported to be a
valid measurement tool.
Half of all the studies reviewed (23/37 studies) used
validated tools. In 1999, Davis4 found that studies often did
not use standardized, validated measures. Several mea-
surement tools currently in routine use had been available
for only a few years in 1999. Based on our review and on
the previous literature, it seems that although the psycho-
metric properties of several PRO and clinician-reported
outcome measures have been extensively studied in the last
decade, performance outcome measures lack quality in this
field.2
In a systematic review of objective measurement
methods, Furtado et al.2 found that only a few studies
investigated aspects of validity of outcome measures. For
example, they found that only 1 in 18 studies investigated
reliability. They concluded that this raises questions about
the accuracy of the objective (in our terminology, perfor-
mance outcome) measures and veracity of the results.2
FO of Lower-Extremity STS Patients
The data sample in the current review included a
heterogeneous group of lower-extremity STS patients.
According to the current review and analysis, the postop-
erative FO for patients is relatively good. The mean
postoperative FO measured by MSTS for patients with
extremity osteosarcoma is reported to range between 40%
and 76.6%.78 In pediatric bone sarcoma patients, the
reported postoperative MSTS mean scores ranged from
76% to 82.5%.7 In a review of pelvic sarcoma patients, the
mean MSTS score was 65%.8
Amputation seems to decrease FO.23,78 Our FO data
included relatively few articles on amputation. The MSTS
1993 FO analysis did not include any articles and the TESS
analysis included only two articles on amputations.23,42 In
the work of Davis et al.42 the mean TESS score for the
patients with amputations was 74.5 versus 85.1 for the
patients with limb-sparing procedures. In the study by
Furtado et al.23 the mean TESS score was only 56.4. Han
et al.78 performed a meta-analysis of osteosarcoma patients
and observed that the number of amputation patients was
relatively higher. The mean MSTS for the amputation
patients ranged from 41.1% to 71% versus 70% to 76.6%
for the patients with limb-sparing procedures, which is
lower than the result of the current review. As expected,
some studies show that amputation decreases FO,23,78
whereas others have failed to show a significant difference
compared with limb-sparing treatment.79–81 Based on this
review, lower-extremity STS patients seem to achieve
preoperative function levels postoperatively during long-
term follow-up evaluation ([ 1 year).
The Quality of the Publications Reporting FO
This review included different types of studies exam-
ining varied methodologic quality. The use of the MINORS
tool showed that most studies investigating lower-extrem-
ity STS FO are lacking in methodologic quality (median
MINORS score, 62.4%; range, 31–92).
This is the first systematic review of FO measurement to
focus on lower-extremity STS patients. The strengths of
this review were the use of PRISMA guidelines and the
methodologic quality assessment for this topic. The main
weakness of the current review was the nonstructural
search strategy for validity of FO measurement tools used.
In addition, one exclusion criterion was to have ‘‘fewer
than 20 lower-extremity STS patients in the study (con-
sidered a pilot study).’’ This might have excluded some
relevant studies with small samples. Because the authors
attempted to overview the existing literature on FO mea-
surement of lower-extremity STS patients as thoroughly as
possible, they included some studies containing small
amounts of upper-extremity and bone sarcomas. Because
the number of non–lower extremity STS patients in the
reviewed studies was small (88% lower-extremity and 94%
STS patients), and because the sensitivity analysis pre-
sented similar FO results for publications reporting on
upper-extremity or bone sarcoma patients, the effect on FO
results was small.
CONCLUSION
The most frequently used FO measurements for surgi-
cally treated adult lower-extremity STS patients are
clinician-reported outcome and PRO measurements. The
most widely used measure is the patient-reported TESS
instrument, which has been shown to produce reliable and
valid scores in assessing FO for lower-extremity sarcoma
patients. Using the TESS and MSTS measures allows for
benchmarking and comparison of results with other studies.
Functional outcome scores seem to return to pretreatment
levels 1 year after surgery. Thus, measurement of FO also
should be performed at least once 1 year after surgery or
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later in addition to other time points. This review indicates
that quality is lacking in FO studies examining surgical
treatment of lower-extremity STS.
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